TOKYO, Dec 1, 2021 - (JCN Newswire via SEAPRWire.com) - NEC Corporation (TSE: 6701) today announced the development of a "gradual deep learning-based object detection technology" that enables efficient and high throughput object detection for video analytics while maintaining detection accuracy.This technology enables up to eight times the processing speed of object detection for large volumes of images, even on edge devices with limited processing capacity.NEC aims to commercialize this technology in fiscal 2022, following further research and development.Video analytics are expected to be utilized for a wide range of applications, such as analyzing camera images of vehicles at intersections, optimizing traffic control, and analyzing camera images of stores and warehouses to detect intrusion or to optimize facility management.To perform these video analytics in real time, it is ideal to process them on an edge device near a sensor, such as a camera.However, because cooling is difficult to manage and electricity consumption is restricted in edge devices, high-performance processors such as GPUs used in high-performance servers are not available, and processing capacity is constrained.In video analytics, object detection software that utilizes deep learning (hereinafter "object detection AI model") performs object detection processing in order to find the object to be analyzed from images captured by a cameraSince highly accurate object detection AI models have a large amount of operations though, it is difficult for edge devices to process a large amount of images due to constraints on processing capacity. If the amount of operations for a high-speed object detection AI model is reduced, for example, the accuracy declines and the recognition accuracy requirements for image analysis cannot be met.Application of NEC's newly developed gradual deep learning-based object detection technology enables efficient, high-speed, and high-precision detection of subjects from a large amount of images, even in an edge device with limited processing capacity, and enables simultaneous processing of images from multiple cameras in real time.Technology Features1. High-speed, high-precision detection at the same timeThis technology combines an object detection AI model that is high-speed, but is only roughly accurate, with another object detection AI model that is highly accurate, but computationally complex. This combination enables efficient processing of multiple images and results in high-speed, high-precision detection.First, a high-speed object detection AI model detects multiple objects quickly, but with rough accuracy, then the detected results are processed together with a high-precision object detection AI model to gradually refine the detected objects.As a result, in an example of detecting a car license plate from a camera image, processing speed was approximately eight times faster than when using an object detection AI model with high accuracy alone, while maintaining detection accuracy*.2. Compatible with various detection targets, detection methods, and AI chipsThis technology is compatible with a diverse range of object detection processes according to detection targets, such as people, vehicles and car license plates, without being limited to specific detection targets and specific processing methods.In addition, the technology's application is not limited to a specific AI chip. By taking advantage of the fact that AI chips have a large number of computing resources in common, the technology makes effective use of the internal computing power of chips.Going forward, NEC aims to enhance the safety, security, and convenience of society by expanding the use of video analytics technologies to a wide variety of applications.*Speed varies depending on the device used, the type of detection engine and the quality of image data.About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)
TOKYO, Nov 1, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. and PRISM BioLab Co., Ltd. announced today that the CREB-binding protein (CBP) / beta-catenin inhibitor E7386, a medium-molecular weight compound created through collaboration research between Eisai and PRISM, has achieved the clinical POC (Proof of Concept).Eisai is conducting a Phase I clinical study of E7386 monotherapy for solid tumors, and a Phase Ib clinical trial of E7386 plus lenvatinib mesylate (product name: LENVIMA, "lenvatinib"), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for solid tumors including hepatocellular carcinoma. The achievement of the POC, which is defined in a collaborative research agreement between Eisai and PRISM, was confirmed based on data such as antitumor activity and changes of biomarkers in these clinical trials.The E7386 targets, beta-catenin, is considered to be one of the undruggable targets that are particularly difficult to develop into drug discovery. beta-catenin, along with CBP, which is also the target of E7386, is located at the downstream of the Wnt signaling and regulates the Wnt signaling-dependent transcription activity. E7386 is a CBP / beta-catenin inhibitor that inhibits CBP and beta-catenin protein-protein interactions and regulates the Wnt signal-dependent gene expression. It is expected to suppress tumor growth dependent on the Wnt signaling. 1 E7386 is also expected to release the suppression of tumor-infiltrating T cells by the Wnt signaling activation, and to enhance the effect of immune checkpoint inhibitors1. The antitumor effect of E7386 alone and the combination of E7386 and anti-PD-1 antibody has been confirmed in a cancer-bearing mouse model.(1)Based on the POC achievement, Eisai has initiated a phase Ib/II clinical trial (Study 201) of E7386 in combination with anti-PD-1 therapy pembrolizumab for solid tumors in Japan.*Dr. Takashi Owa, Senior Vice President, President of Oncology Business Group, at Eisai said, "With achieving the POC, we are confident with the prospect of offering E7386 to patients as a cancer treatment. E7386 may overcome lenvatinib and pembrolizumab treatment resistances through its combination therapy with lenvatinib or pembrolizumab. Eisai will accelerate clinical trials of E7386 in combination with lenvatinib or pembrolizumab, and do its utmost aiming to create new treatments for cancers with high unmet medical needs."Dai Takehara, President and CEO of PRISM commented, "The approval of the clinical POC for the E7386 demonstrates that PRISM's drug discovery platform is an effective option for novel drug targets which have been considered difficult. We are grateful to Eisai for advancing this development. We will continue to take on the challenge of targeting more novel targets, with the aim of providing new treatment to as many patients as possible."* Study 201 is being conducted under a clinical trial collaboration and supply agreement between Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A.About EisaiEisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology.In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals.For further information on Eisai Co., Ltd., please visit https://www.eisai.com and connect with us on Twitter @Eisai_SDGs. About PRISM BioLab PRISM BioLab Co., Ltd., is a biotechnology company with proprietary small molecule drug discovery platform "PepMeticsTM Technology". The PepMeticsTM Molecules are designed to mimic alpha-helix or beta-turn peptide using a unique stable scaffold with corresponding dihedral angles. These motifs are essential for protein-protein interactions within the cell, especially related to transcription and translation. Using our small molecule drug discovery technology, two clinical-stage assets for cancer and fibrosis have been developed and licensed. Further, PRISM is working on new drug targets in collaboration with Global and Japanese pharmaceutical companies. About Wnt Wnt is a glycoprotein with a molecular weight of about 40,000, which is conserved across organisms from nematodes and Drosophila to mammals, and it is reported to control early development, morphogenesis, organogenesis, and cell proliferation, differentiation, and motility after birth. Pathways known to comprise the Wnt signaling pathway include the Wnt / beta-catenin pathway which is associated with cell differentiation and dorsal formation, the Wnt / PCP pathway which is involved in planar cell polarity and motility during gastrulation, the Wnt / Ca2+ pathway which plays a role in embryonic isolation and the pathway involved in the regulation of muscle regeneration. The most well-known Wnt signaling is the Wnt / beta-catenin pathway. It has been reported that beta-catenin induces gene expression as a mediator of Wnt signaling, and as a result regulates cell proliferation and differentiation. beta-catenin, along with RAS, P53 and MYC, is called "Cancer's Big 4" and is considered to be one of the undruggable targets that are difficult to develop into drug discovery. About E7386 E7386 is a CBP / beta-catenin inhibitor that inhibits protein-protein interactions between the transcription coactivator CBP and beta-catenin, and regulates the Wnt signaling-dependent gene expression. Since E7386 acts on the CBP / beta-catenin transcription complex located at the most downstream of the Wnt signaling, it is expected to inhibit not only ligand- dependent activation but also activation caused by gene mutations in Wnt signaling factors such as adenomatous polyposis coli (APC) and beta-catenin. (1) Cancer Res. 2021 Feb 15;81(4):1052-1062. https://cancerres.aacrjournals.org/content/81/4/1052.full-text.pdf Media Inquiries: Eisai Co., Ltd., Public Relations Department TEL: +81-(0)3-3817-5120 PRISM BioLab Co., Ltd. TEL: +81-(0) 466-53-8383 Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)
Good morning! Here are our top stories to kick-start your Saturday, Oct 23. Justin Lee, who fell to his death after drug arrest, treated professionally and fairly by officers: CNB CNB had launched probe after his mother posted a letter addressed to Shanmugam on her Instagram page. READ MORE HERE Rise of Covid-19 vaccine sceptics: Time for the moderate middle to speak up Vaccine sceptics say they distrust official sources. Professional medical bodies can help by stepping up to plug the information gap. READ MORE HERE 14 Singaporeans die from Covid-19 complications; 3,637 new infections A vaccinated 41-year-old who was immuno-compromised and had severe underlying lung disease was among those who died. READ MORE HERE More on this topic Related Story ST newsletters: Get alerts on the latest news Singapore bride-to-be tests positive for Covid-19 five days before her wedding With the surge in Covid-19 cases in the past two months, solemnisers interviewed say they are seeing couples having to postpone their nuptials. READ MORE HERE Still risk of healthcare system reaching tipping point While the pressure is great, experts say the current curbs provide time for more to be vaccinated. READ MORE HERE Can Singapore's climate targets be more ambitious? Its plans to achieve net zero emissions are vague and its shorter-term climate goal of having its emissions peak by 2030 has drawn criticism. READ MORE HERE Asia’s power crisis: Pain and gain The Straits Times bureaus report on the impact of the surge in oil, natural gas and coal prices across the Asia-Pacific. READ MORE HERE Peru's ancient wonders: 12 heritage sites From ancient sanctuaries to prehistoric habitats, Peru’s Unesco World Heritage Sites reveal clues about one of the world’s cradles of civilisation. READ MORE HERE Former POSB chief executive Bertie Cheng dies of Covid-19 at 84 Elder son Melvin Cheng said his father rarely fell ill and had cut back on going out during the pandemic. READ MORE HERE Alec Baldwin says 'my heart is broken' after fatal movie set shooting Cinematographer Halyna Hutchins died when the Hollywood star fired a prop gun on a New Mexico movie set. READ MORE HERE
SINGAPORE - It is T-minus seven days to COP26, and the British host of the United Nations climate talks is urging world leaders to arrive in Glasgow with bolder climate pledges. In the lead-up to the annual meeting - postponed by a year because of the Covid-19 situation last year - more than 110 countries have already said they intend to have their planet-warming emissions reach net zero by a certain timeline. Please subscribe or log in to continue reading the full article. Get unlimited access to all stories at $0.99/month Latest headlines and exclusive stories In-depth analyses and award-winning multimedia content Get access to all with our no-contract promotional package at only $0.99/month for the first 3 months* Subscribe now *Terms and conditions apply.
TOKYO, Apr 16, 2021 - (JCN Newswire via SEAPRWire.com) - Fujitsu today announced a significant update to its greenhouse gas reduction targets as efforts towards decarbonization gain increasing urgency and accelerate throughout the world. To contribute more aggressively to the resolution of environmental issues confronting humanity, Fujitsu revised its emissions reduction targets for its business sites in FY 2030 from 33% to 71.4% below FY 2013 levels. On April 15, these were successfully validated as 1.5 degC-aligned targets by the Science Based Targets initiative (SBTi, 1).Fujitsu simultaneously issued the "Fujitsu Group Environmental Action Plan (Stage X)," which will guide stakeholders throughout the global organization in contributing to the achievement of its environmental targets for FY 2021 and FY 2022.Fujitsu's Environmental Action Plan demonstrates its ongoing commitment to proactively reducing the environmental footprint of its business activities, including throughout its supply chain, and will continue contributing to the decarbonization of customers and society, adapt to mitigate the harmful impacts of climate change, and resolve pressing environmental and social issues through technology.BackgroundIn May 2017, Fujitsu first formulated its medium- and long-term environmental vision, "Fujitsu Climate and Energy Vision," and in August of the same year, obtained SBT certification for 2degC-aligned emissions reduction targets. The SBTis are intended to significantly reduce GHG emissions over the medium to long term based on scientific knowledge compiled by the IPCC (2) and other organizations.The Global Risks Report 2021 identifies "Natural resource crisis" and "Biodiversity loss" in addition to "Climate action failure" as environmental risks posing a high impact and high probability of occurrence. Bearing these factors in mind, Fujitsu has set targets for the two years from FY 2021 as the "Fujitsu Group Environmental Action Plan (Stage X )" under three key areas.Overview of "Fujitsu Group Environmental Action Plan (Stage X)"Fujitsu is identifying priority areas based on the life cycle of the products and services it provides and will set and promote nine targets from the three perspectives of "Climate change," "Resource circulation," as well as "Co-existence with nature."In the area of "Climate Change," Fujitsu will strategically promote energy conservation and the introduction of renewable energy resources by leveraging advanced technologies to achieve emissions reductions targets aligned with 1.5degC, in order to achieve our targets for decarbonization and mid- to long-term GHG reduction. With regard to "Resource circulation," Fujitsu will strengthen its efforts to collect information on water and measures to mitigate the impacts of climate change from suppliers using the CDP Supply Chain Program (3) to promote the resource-saving design of products (focus on measures for reuse and reduce the use of plastic) as well as understanding and reducing environmental impact throughout the supply chain. In the "Co-existence with nature" area, Fujitsu will set new targets for visualizing the impact of corporate activities on biodiversity.(1) SBTi (Science Based Targets initiative):An initiative jointly established by the United Nations Global Compact, the World Resources Institute (WRI: World Resources Institute), and other organizations in 2015. It encourages companies to set GHG emission reduction targets consistent with science-based evidence to the level required by the Paris Agreement, validating targets that comply with criteria including indirect emissions not only within the company but also in the supply chain.(2) IPCC (Intergovernmental Panel on Climate Change):An abbreviation for "United Nations Intergovernmental Panel on Climate Change" established in 1988 by the United Nations Environment Programme (UNEP) and the World Meteorological Organization (WMO) for the purpose of carrying out comprehensive assessments from scientific, technological and socio-economic perspectives on anthropogenic climate change, impacts, adaptation and mitigation measures.(3) CDP Supply Chain Program:The CDP is an international non-profit organization that manages global disclosure for companies' activities relating to climate change, forests, and water security, on behalf of institutional investors that have total investment assets in excess of $110 trillion. The CDP Supply Chain Program is a scheme in which companies, governments, and other program members request suppliers to respond to a survey on environmental impact, and the results are fed back to the program members.About FujitsuFujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 130,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.9 trillion yen (US$35 billion) for the fiscal year ended March 31, 2020. For more information, please see www.fujitsu.com. Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)
TOKYO, Feb 2, 2021 - (JCN Newswire) - NTT DOCOMO announced that its ambitious greenhouse gas reduction targets by 2030 have been validated by the Science-Based Targets initiative (SBTi), an international undertaking to certify that greenhouse gas reduction targets of enterprises are consistent with scientific evidence. DOCOMO is the first Japanese mobile carrier to receive such validation from the SBTi.As part of the validation process, DOCOMO developed science-based targets in line with SBTi criteria, including emissions-reduction targets to limit temperature increases to 1.5degC above the pre-industrial level.DOCOMO's Scope 1 targets for direct emissions resulting from fuel use within the company and Scope 2 targets for indirect emissions associated with the use of externally purchased electricity and heat both target 50% reductions in emissions, which would lead to accomplishing the goal to limit global warming to 1.5degC above pre-industrial level by 2030 compared to the base year of fiscal year 2018. Also, the company's Scope 3 targets for indirect emissions from the entire value chain other than Scope 1 and 2 emissions call for 14% reductions by 2030 compared to the base year of fiscal year 2019.SCIENCE BASED TARGETS DRIVING AMBITIOUS CORPORATE CLIMATE ACTION logoThe various targets accord with the DOCOMO Group Environmental Declaration, a vision for a better future for the earth, and the company's Green Action Plan 2030 covering environmental targets to be achieved by the year 2030. To achieve these targets, DOCOMO will act to widely utilize renewable energy, reduce greenhouse gas emissions throughout its supply chain and utilize ICT technology for decarbonization.Going forward, DOCOMO will continue to strengthen its development initiatives to help realize a more sustainable society where all generations can enjoy safe, secure and comfortable lives that transcend conventional boundaries.About NTT DOCOMONTT DOCOMO, Japan's leading mobile operator with over 80 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations. https://www.nttdocomo.co.jp/english/. Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com